WO2009112232A3 - New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen - Google Patents

New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen Download PDF

Info

Publication number
WO2009112232A3
WO2009112232A3 PCT/EP2009/001688 EP2009001688W WO2009112232A3 WO 2009112232 A3 WO2009112232 A3 WO 2009112232A3 EP 2009001688 W EP2009001688 W EP 2009001688W WO 2009112232 A3 WO2009112232 A3 WO 2009112232A3
Authority
WO
WIPO (PCT)
Prior art keywords
drospirenone
phase
regimen
estradiol
amount
Prior art date
Application number
PCT/EP2009/001688
Other languages
French (fr)
Other versions
WO2009112232A2 (en
Inventor
Vladimir Hanes
Rolf Schürmann
Bernd Düsterberg
Joachim Marr
Hartmut Blode
Original Assignee
Vladimir Hanes
Schuermann Rolf
Duesterberg Bernd
Joachim Marr
Hartmut Blode
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vladimir Hanes, Schuermann Rolf, Duesterberg Bernd, Joachim Marr, Hartmut Blode filed Critical Vladimir Hanes
Publication of WO2009112232A2 publication Critical patent/WO2009112232A2/en
Publication of WO2009112232A3 publication Critical patent/WO2009112232A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a triphasic pharmaceutical combination product with 24 consecutive daily dosage units in its three phases comprising in each phase of the triphasic product 6 to 10 daily dosage units wherein the amount of drospirenone decreases from 3.0 mg of drospirenone in each daily dosage unit in the first phase to 1.5 mg of drospirenone in each daily dosage unit in the third phase and wherein the amount of drospirenone in each daily dosage unit of the second phase is more than 1.5 mg and less than 3.0 mg and wherein the amount of 17β-estradiol increases from 1.0 mg in each dosage unit in the first phase to an amount of 2.0 mg of 17β-estradiol in the third phase and wherein the amount of 17β-estradiol in each daily dosage unit of the second phase is more than 1.0 mg and less than 2.0 mg and 4 active ingredient-free placebo pills or other indications to show that the daily administration of the 24 dosage units is to be followed by 4 pill-free or placebo pill days.
PCT/EP2009/001688 2008-03-10 2009-03-10 New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen WO2009112232A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US3528508P 2008-03-10 2008-03-10
US61/035,285 2008-03-10
US3620708P 2008-03-13 2008-03-13
US61/036,207 2008-03-13
US4039708P 2008-03-28 2008-03-28
US61/040,397 2008-03-28

Publications (2)

Publication Number Publication Date
WO2009112232A2 WO2009112232A2 (en) 2009-09-17
WO2009112232A3 true WO2009112232A3 (en) 2010-07-22

Family

ID=40653548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/001688 WO2009112232A2 (en) 2008-03-10 2009-03-10 New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen

Country Status (2)

Country Link
TW (1) TW200946542A (en)
WO (1) WO2009112232A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012026115B1 (en) * 2010-04-15 2019-12-24 Bayer Ip Gmbh solid oral dosage form, its use, and packaging unit

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253607A1 (en) * 1986-07-15 1988-01-20 American Home Products Corporation Combination dosage form for premenopausal women
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1380301A1 (en) * 1999-08-31 2004-01-14 Schering Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and dropirenone for use as a contraceptive
WO2005049142A2 (en) * 2003-11-14 2005-06-02 Warner Chilcott Company, Inc. Graduated estrogen contraceptive
WO2006120035A2 (en) * 2005-05-13 2006-11-16 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253607A1 (en) * 1986-07-15 1988-01-20 American Home Products Corporation Combination dosage form for premenopausal women
EP1380301A1 (en) * 1999-08-31 2004-01-14 Schering Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and dropirenone for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
WO2005049142A2 (en) * 2003-11-14 2005-06-02 Warner Chilcott Company, Inc. Graduated estrogen contraceptive
WO2006120035A2 (en) * 2005-05-13 2006-11-16 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate

Also Published As

Publication number Publication date
WO2009112232A2 (en) 2009-09-17
TW200946542A (en) 2009-11-16

Similar Documents

Publication Publication Date Title
NZ605176A (en) Pharmaceutical composition comprising drospirenone and contraceptive kit
NO20091954L (en) Use of ostradiol valerate or 17β-ostradil in combination with dienogest for oral therapy to maintain and / or increase female libido
WO2011053653A3 (en) Prevotella histicola preparations and the treatment of autoimmune conditions
WO2010066749A3 (en) Ulipristal acetate tablets
TW200600120A (en) Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance
HRP20240121T1 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
HRP20170734T1 (en) Increasing drug bioavailability in naltrexone therapy
JP2018527305A5 (en)
JP2013544290A5 (en)
MX2018000084A (en) Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin.
SI2906233T1 (en) Formulations for the treatment and prevention of obesity
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
WO2008122439A3 (en) Dr0spiren0ne/17beta-estradi0l regimen, pharmaceutical combination product and kit for performing this regimen
WO2009112232A3 (en) New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
CY1108265T1 (en) STRONG INTERMEDIATE PHARMACEUTICAL FORM FOR CONTRACT
WO2009112231A3 (en) Drospirenone/ 17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2011119649A3 (en) Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs
WO2011108882A3 (en) Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient
WO2010142400A3 (en) Chitosan oligosaccharide-based compositions
CR10912A (en) FRAMACEUTICAL PREPARATION TO REDUCE ENDOMETRIOSIS
UA85003C2 (en) Solid peroral contraceptive drug
HRP20161166T1 (en) Tapentadol for use in the treatment of irritable bowel syndrome
WO2016028903A8 (en) Oral transmucosal pharmaceutical compositions including testosterone and a c-serm
HRP20200155T1 (en) Pharmaceutical composition comprising drospirenone and contraceptive kit

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09719770

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09719770

Country of ref document: EP

Kind code of ref document: A2